TransCode Therapeutics Inc (NASDAQ:RNAZ) currently has a daily average trading volume of 57.60K but it saw 95599 shares traded in last market. With a market cap of 2.39M USD, the company’s current market price of $3.43 came falling about -4.99 while comparing to the previous closing price of $3.61. In past 52 weeks, the stock remained buoying in the range of price level as high as $236.94 and as low as $3.21. In the recent trading on the day, stock has struck highest price mark of $3.35 while lowest mark touched by it was $3.71.
Taking a look at 20-day trading activity of TransCode Therapeutics Inc (RNAZ) gives us an average price of $4.75, while its current price level is -98.55% below from 52-week high level whereas it is 6.85% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $9.57 while that of 200 days or SMA-200 reads an average of $19.39. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.66% during that period while stretching the period over a month that decreases to 12.33%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 27.65 which implies that the stock is in oversold territory.
Over the week, RNAZ’s stock price is moving 1.78% up while it is -55.63% when we observe its performance for the past one month. Year-to-date it is 1.78% up and over the past year, the stock is showing a downside performance of -98.20%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -3.21 while estimate for next year EPS is -4.76. Moreover, analysts are in estimates of $300k for current-quarter revenue.
Currently, TransCode Therapeutics Inc’s total number of outstanding shares is 0.70M. Company’s return on investment (ROI) stands at -903.45% and return on equity (ROE) at -490.03%. Stock’s beta reads 0.75. Stock has a price to book (P/B) ratio of 1.09. Its return on asset (ROA) is -210.77% on average.
